Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Blood (2025) 146 (Supplement 1): 251.

https://doi.org/10.1182/blood-2025-251

Published: 2025

Journal Articles

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Blood (2025) 146 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2025-5720

Published: 2025

Journal Articles

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Blood (2025) 146 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2025-3927

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Blood (2025) 146 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2025-3920

Published: 2025

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large B Cell Lymphoma

Bachisio Ziccheddu, Michael D. Jain, Monika Chojnacka, Michael Durante, Venu Venkatarame Gowda Saralamma, Austin Daniel Newsam, Jerald Noble, Nicholas B Figura, Meghan Menges, Ola Landgren, Marco Davila, Jonathan H. Schatz, Francesco Maura, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 232.

https://doi.org/10.1182/blood-2024-208372

Published: 2024

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Marios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, Holly Lee, John McIntyre, Marietta Truger, Michael Durante, Bachisio Ziccheddu, Ola Landgren, Leo Rasche, Nizar J. Bahlis, Paola Neri, Francesco Maura

Blood (2024) 144 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2024-212294

Published: 2024

Journal Articles

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Blood (2024) 144 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2024-200927

Published: 2024

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Clinical Impact of Neoantigen Burden and HLA Loss in Aggressive B-Cell Lymphomas Treated with CD19 CAR T-Cell

Bachisio Ziccheddu, Michael D. Jain, Monika Chojnacka, Michael Durante, Julieta Abraham Miranda, Meghan Menges, Ola Landgren, Marco Davila, Jonathan H. Schatz, Francesco Maura, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2023-182821

Published: 2023

Journal Articles

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Holly Lee, Sungwoo Ahn, Ranjan Maity, Noémie Leblay, Michael Durante, Bachisio Ziccheddu, Alexis Brake, Remi Tilmont, Elie Barakat, Mansour Poorebrahim, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2023-190517

Published: 2023

Journal Articles

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Holly Lee, Michael Durante, Sungwoo Ahn, Noemie Leblay, Mansour Poorebrahim, Ranjan Maity, Rémi Tilmont, Elie Barakat, David Jung, Bachisio Ziccheddu, Alexis Brake, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2023-188080

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomics define neoplastic transformation in multiple myeloma precursor conditions

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large B Cell Lymphoma

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Clinical Impact of Neoantigen Burden and HLA Loss in Aggressive B-Cell Lymphomas Treated with CD19 CAR T-Cell

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only